Stay updated with breaking news from Genentech. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
In a review, investigators focused on ranibizumab (Lucentis; Genentech), aflibercept (Eylea; Regeneron), and bevacizumab (Avastin; Genentech) as growth opportunities in the biosimilar space.
Dublin, April 09, 2024 (GLOBE NEWSWIRE) -- The
Despite the availability of anti-VEGF therapies, there is still a notable disease burden in older adults with vision-threatening retinal diseases.
/PRNewswire/ -- The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) is pleased to announce approximately $10M in planned project...
NIIMBL Announces $10M for 8 New Biopharmaceutical Manufacturing Projects